Conference CallTrying to fnd positives.
Seems they expect margins to improve by 5% in 2017.
Sales were excellerated in the third quarter by distributor load ins especially in critical drugs
Their business model only looks at aquisitions in the $50-150 mil range and they have a number in the Q, two that are getting close.
They are not worried about no-name drugs as they believe they have a good legal position in all their trading areas and generics have not even been discussed so far as an issue.
Personal observation: They sound like an analytical pragmatic bunch with a solid plan that they are sticking to. there are no cheerleaders in the group and I thought a little more life and excitement about who they are , where they are going and how everyone will benefit might have helped this call. However this may be the norm in the Pharma catagorey.
Again I get the impression , although they would not talk 2018 guidance, that all roads lead to the spring of 2018 as the merge point of all there efforts. The question is will the market buy in and hold for those positiive results.
Many of the analysts will no doubt modify their guidance in the next little while. We will see what they think.